Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keeping Track: FDA OKs AMAG's Vyleesi, But Bronchitol And Quizartinib Draw CRLs

Executive Summary

The latest drug development news and highlights from our US FDA Performance Tracker.

Advertisement

Related Content

AML Contender Quizartinib Gains First Approval, In Japan
Daiichi’s Quizartinib And The Quintessential 'Pazdur Moment'
Quizartinib Looks Like A Good Drug, ODAC Says, But Needs Another Efficacy Trial Before Approval
Daiichi's AML Drug Quizartinib Heads To ODAC With Host Of Efficacy, Safety Issues
Bronchitol Gets Narrow Approval Vote From Advisory Cmte., Leaving US FDA Host Of Issues To Consider
Chiesi Takes CF Product To Advisory Cmte. With Modest Efficacy, Many Questions
Keeping Track Of The US FDA's Final Approvals Of 2018
Keeping Track: Vitaros Reenters The Wilderness, Remoxy Gives It A Fourth Try, And Two Novel Approvals
Novo Nordisk's Victoza Adds CV Benefit Claim, But Not For Primary Prevention
Pharmaxis Faces New Study Requirement For CF Drug Bronchitol

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS125515

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel